|Bid||109.48 x 800|
|Ask||109.49 x 800|
|Day's range||108.20 - 109.57|
|52-week range||79.11 - 121.53|
|Beta (5Y monthly)||0.83|
|PE ratio (TTM)||29.53|
|Forward dividend & yield||5.20 (4.79%)|
|Ex-dividend date||14 Oct 2021|
|1y target est||N/A|
AbbVie's (ABBV) third-quarter results are expected to reflect the impact of a strong recovery in demand for new drugs. Investors are likely to focus on any update related to guidance.
Investors in search of stable income should consider strong dividend-paying stocks, with solid yields. Pharmaceutical standout AbbVie appears to be worth buying as a long-term play, with it set to release its Q3 results on Friday, October 29...
AbbVie (ABBV) closed at $108.50 in the latest trading session, marking a -0.59% move from the prior day.